Immunological influence of sizofiran in patients with cancer of the head

Sizofiran (SPG), a biological response modifier, was administered to 34 patients with head and neck cancer, to clarify the significance of administration of SPG during anti-cancer treatment. NK activity, lymphocytes, and lympho-blastomic ratio decreased in all patients, but these parameters tended t...

Full description

Saved in:
Bibliographic Details
Published injibi to rinsho Vol. 36; no. 6; pp. 1200 - 1206
Main Authors OKADA, Takuya, YOSHIDA, Tomoyuki, SAEKI, Tetsuo, AOYAMA, Yumiko, OKUDAIRA, Tadao, FUNASAKA, Soutaro
Format Journal Article
LanguageJapanese
Published JIBI TO RINSHO KAI 20.11.1990
Subjects
Sizofiran (SPG)
Online AccessGet full text

Cover

More Information
Summary:Sizofiran (SPG), a biological response modifier, was administered to 34 patients with head and neck cancer, to clarify the significance of administration of SPG during anti-cancer treatment. NK activity, lymphocytes, and lympho-blastomic ratio decreased in all patients, but these parameters tended to return to normal levels in the SPG group earlier than they did in the non-administered group. IAP was inhibited significantly after treatment with SPG. CD8+ cells were increased in the SPG group and two color flow cytometry revealed that this increase was due to a significant increase of CD8+ CD11+ group and the dull CD8+ CD11+ group. These results suggest that administration of SPG to head and neck cancer contribute to earlier recovery of immunocompetence after anticancer treatments.
ISSN:0447-7227
2185-1034
DOI:10.11334/jibi1954.36.6_1200